P53 family: Role of protein isoforms in human cancer

Journal of Nucleic Acids

Volumn 2012, Issue , 2012, Pages

  Wei, Jinxiong ^a   Zaika, Elena ^a   Zaika, Alexander ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROTEIN; PROTEIN P53; PROTEIN P63; PROTEIN P73;

ALTERNATIVE RNA SPLICING; CARCINOGENESIS; CELL FUNCTION; GENE EXPRESSION; GENETIC VARIABILITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REGULATORY MECHANISM; REVIEW; TP53 GENE; TP63 GENE; TP73 GENE; TREATMENT RESPONSE;

EID: 84859865843     PISSN: 20900201     EISSN: 2090021X     Source Type: Journal    
DOI: 10.1155/2012/687359     Document Type: Review

References (171)

1. Wang E. T., Sandberg R., Luo S., Khrebtukova I., Zhang L., Mayr C., Kingsmore S. F., Schroth G. P., Burge C. B., Alternative isoform regulation in human tissue transcriptomes. Nature 2008 456 7221 470 476 (Pubitemid 352759009)
2. Pan Q., Shai Q., Lee L. J., Frey B. J., Blencowe B. J., Deep surveying of alternative splicing complexity in the human transcriptome by high-throughput sequencing. Nature Genetics 2008 40 12 1413 1415
3. Klinck R., Bramard A., Inkel L., Dufresne-Martin G., Gervais-Bird J., Madden R., Paquet É. R., Koh C., Venables J. P., Prinos P., Jilaveanu-Pelmus M., Wellinger R., Rancourt C., Chabot B., Elela S. A., Multiple alternative splicing markers for ovarian cancer. Cancer Research 2008 68 3 657 663 2-s2.0-38849179519 10.1158/0008-5472.CAN-07-2580 (Pubitemid 351206740)
4. Venables J. P., Klinck R., Koh C., Gervais-Bird J., Bramard A., Inkel L., Durand M., Couture S., Froehlich U., Lapointe E., Lucier J. F., Thibault P., Rancourt C., Tremblay K., Prinos P., Chabot B., Elela S. A., Cancer-associated regulation of alternative splicing. Nature Structural and Molecular Biology 2009 16 6 670 676 2-s2.0-67349097457 10.1038/nsmb.1608
5. Bourdon J. C., Fernandes K., Murray-Zmijewski F., Liu G., Diot A., Xirodimas D. P., Saville M. K., Lane D. P., p53 isoforms can regulate p53 transcriptional activity. Genes and Development 2005 19 18 2122 2137 2-s2.0-24344448786 10.1101/gad.1339905 (Pubitemid 41330315)
6. Dötsch V., Bernassola F., Coutandin D., Candi E., Melino G., p63 and p73, the ancestors of p53. Cold Spring Harbor perspectives in biology 2010 2 9 a004887
7. Rutkowski R., Hofmann K., Gartner A., Phylogeny and function of the invertebrate p53 superfamily. Cold Spring Harbor Perspectives in Biology 2010 2 7 a001131 2-s2.0-77958168866 10.1101/cshperspect.a001131
8. Petre-Lazar B., Livera G., Moreno S. G., Trautmann E., Duquenne C., Hanoux V., Habert R., Coffigny H., The role of p63 in germ cell apoptosis in the developing testis. Journal of Cellular Physiology 2007 210 1 87 98 2-s2.0-33845428535 10.1002/jcp.20829 (Pubitemid 44904704)
9. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J. C., Valent A., Minty A., Chalon P., Lelias J. M., Dumont X., Ferrara P., McKeon F., Caput D., Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 1997 90 4 809 819 2-s2.0-0030812331 10.1016/S0092-8674(00)80540-1 (Pubitemid 27357971)
10. Yang A., Kaghad M., Wang Y., Gillett E., Fleming M. D., Dötsch V., Andrews N. C., Caput D., McKeon F., p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Molecular Cell 1998 2 3 305 316 2-s2.0-0032161624 (Pubitemid 128379271)
11. Melino G., Lu X., Gasco M., Crook T., Knight R. A., Functional regulation of p73 and p63: development and cancer. Trends in Biochemical Sciences 2003 28 12 663 670 2-s2.0-0345059168 10.1016/j.tibs.2003.10.004 (Pubitemid 37500901)
12. Lane D. P., Crawford L. V., T antigen is bound to a host protein in SV40 transformed cells. Nature 1979 278 5701 261 263 2-s2.0-0018348655 (Pubitemid 9129076)
13. Linzer D. I. H., Levine A. J., Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. Cell 1979 17 1 43 52 2-s2.0-0018760324 (Pubitemid 9188209)
14. Sayan A. E., Rossi M., Melino G., Knight R. A., p73: in silico evidence for a putative third promoter region. Biochemical and Biophysical Research Communications 2004 313 3 765 770 2-s2.0-0347063996 10.1016/j.bbrc.2003.12.014 (Pubitemid 38021896)
15. Vilgelm A. E., Washington M. K., Wei J., Chen H., Prassolov V. S., Zaika A. I., Interactions of the p53 protein family in cellular stress response in gastrointestinal tumors. Molecular Cancer Therapeutics 2010 9 3 693 705 2-s2.0-77949737597 10.1158/1535-7163.MCT-09-0912
16. Yang A., McKeon F., p63 and p73: p53 mimics, menaces and more. Nature Reviews Molecular Cell Biology 2000 1 3 199 207 2-s2.0-0034576495
17. Stiewe T., Theseling C. C., Pützer B. M., Transactivation-deficient ΔTA-p73 inhibits p53 by direct competition for DNA binding. Implications for tumorigenesis. Journal of Biological Chemistry 2002 277 16 14177 14185 2-s2.0-0037134475 10.1074/jbc.M200480200 (Pubitemid 34968030)
18. Ishimoto O., Kawahara C., Enjo K., Obinata M., Nukiwa T., Ikawa S., Possible oncogenic potential of ΔNp73: a newly identified isoform of human p73. Cancer Research 2002 62 3 636 641 2-s2.0-0036468249 (Pubitemid 34126932)
19. Yin Y., Stephen C. W., Luciani M. G., Fåhraeus R., p53 stability and activity is regulated by Mdm2-mediated induction of alternative p53 translation products. Nature Cell Biology 2002 4 6 462 467 2-s2.0-0036307307 10.1038/ncb801 (Pubitemid 34746166)
20. Courtois S., Verhaegh G., North S., Luciani M. G., Lassus P., Hibner U., Oren M., Hainaut P., ΔN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 2002 21 44 6722 6728 2-s2.0-0037015397 (Pubitemid 35221914)
21. Marcel V., Perrier S., Aoubala M., Ageorges S., Groves M. J., Diot A., Fernandes K., Tauro S., Bourdon J. C., Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS Letters 2010 584 21 4463 4468 2-s2.0-78049282442 10.1016/j.febslet.2010.10.005
22. Zaika A., Irwin M., Sansome C., Moll U. M., Oncogenes induce and activate endogenous p73 protein. Journal of Biological Chemistry 2001 276 14 11310 11316 2-s2.0-0035815677 10.1074/jbc.M005737200 (Pubitemid 38089320)
23. Zaika A. I., Kovalev S., Marchenko N. D., Moll U. M., Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Research 1999 59 13 3257 3263 2-s2.0-0033168066 (Pubitemid 29316031)
24. de Laurenzi V., Catani M. V., Terrinoni A., Corazzari M., Melino G., Constanzo A., Levrero M., Knight R. A., Additional complexity in p73: induction by mitogens in lymphoid cells and identification of two new splicing variants ε and ζ Cell Death and Differentiation 1999 6 5 389 390 (Pubitemid 29245951)
25. Ueda Y., Hijikata M., Takagi S., Chiba T., Shimotohno K., New p73 variants with altered C-terminal structures have varied transcriptional activities. Oncogene 1999 18 35 4993 4998 2-s2.0-0033517321 10.1038/sj.onc. 1202817 (Pubitemid 29425306)
26. Vanbokhoven H., Melino G., Candi E., Declercq W., wim.declercq@dmbr.vib- UGent.be p63, a story of mice and men. Journal of Investigative Dermatology 2011 131 6 1196 1207 10.1038/jid.2011.84
27. Mangiulli M., Valletti A., Caratozzolo M. F., Tullo A., Sbisà E., Pesole G., D'Erchia A. M., Identification and functional characterization of two new transcriptional variants of the human p63 gene. Nucleic Acids Research 2009 37 18 6092 6104 2-s2.0-70350674206 10.1093/nar/gkp674
28. Hofstetter G., Berger A., Fiegl H., Slade N., Zori A., Holzer B., Schuster E., Mobus V. J., Reimer D., Daxenbichler G., Marth C., Zeimet A. G., Concin N., Zeillinger R., Alternative splicing of p53 and p73: the novel p53 splice variant p53 is an independent prognostic marker in ovarian cancer. Oncogene 2010 29 13 1997 2004 2-s2.0-77950517696 10.1038/onc.2009.482
29. Dohn M., Zhang S., Chen X., p63 α and ΔNp63 α can induce cell cycle arrest and apoptosis and differentially regulate p53 target genes. Oncogene 2001 20 25 3193 3205 2-s2.0-0034743628 10.1038/sj.onc.1204427 (Pubitemid 32553672)
30. Tomkova K., Belkhiri A., El-Rifai W., Zaika A. I., p73 isoforms can induce T-cell factor-dependent transcription in gastrointestinal cells. Cancer Research 2004 64 18 6390 6393 2-s2.0-4644227579 10.1158/0008-5472.CAN-04-2176 (Pubitemid 39297891)
31. Sauer M., Bretz A. C., Beinoraviciute-Kellner R., Beitzinger M., Burek C., Rosenwald A., Harms G. S., Stiewe T., C-terminal diversity within the p53 family accounts for differences in DNA binding and transcriptional activity. Nucleic Acids Research 2008 36 6 1900 1912 2-s2.0-41849146852 10.1093/nar/gkn044 (Pubitemid 351494234)
32. Graupner V., Schulze-Osthoff K., Essmann F., Jänicke R. U., Functional characterization of p53 β and p53 γ two isoforms of the tumor suppressor p53. Cell Cycle 2009 8 8 1238 1248 2-s2.0-65949091356
33. Avery-Kiejda K. A., Xu D. Z., Adams L. J., Scott R. J., Vojtesek B., Lane D. P., Hersey P., Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. Clinical Cancer Research 2008 14 6 1659 1668 2-s2.0-41549150851 10.1158/1078-0432.CCR-07- 1422 (Pubitemid 351469449)
34. Nakagawa T., Takahashi M., Ozaki T., Watanabe K. I., Todo S., Mizuguchi H., Hayakawa T., Nakagawara A., Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Molecular and Cellular Biology 2002 22 8 2575 2585 2-s2.0-0036203514 10.1128/MCB.22.8.2575-2585.2002 (Pubitemid 34262980)
35. Zaika A. I., Slade N., Erster S. H., Sansome C., Joseph T. W., Pearl M., Chalas E., Moll U. M., δ Np73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. Journal of Experimental Medicine 2002 196 6 765 780 2-s2.0-0037119631 10.1084/jem.20020179
36. Moore H. C., Jordan L. B., Bray S. E., Baker L., Quinlan P. R., Purdie C. A., Thompson A. M., Bourdon J. C., Fuller-Pace F. V., The RNA helicase p68 modulates expression and function of the Δ133 isoform(s) of p53, and is inversely associated with Δ133p53 expression in breast cancer. Oncogene 2010 29 49 6475 6484 2-s2.0-78650029658 10.1038/onc.2010.381
37. Marcel V., Vijayakumar V., Fernández-Cuesta L., Hafsi H., Sagne C., Hautefeuille A., Olivier M., Hainaut P., P53 regulates the transcription of its Δ133p53 isoform through specific response elements contained within the TP53 P2 internal promoter. Oncogene 2010 29 18 2691 2700 2-s2.0-77952239067 10.1038/onc.2010.26
38. Aoubala M., Murray-Zmijewski F., Khoury M. P., Fernandes K., Perrier S., Bernard H., Prats A. C., Lane D. P., Bourdon J. C., p53 directly transactivates Δ133p53 α regulating cell fate outcome in response to DNA damage. Cell Death and Differentiation 2010 18 2 248 258 2-s2.0-77955221488 10.1038/cdd.2010.91
39. Grob T. J., Novak U., Maisse C., Barcaroli D., Lüthi A. U., Pirnia F., Hügli B., Graber H. U., de Laurenzi V., Fey M. F., Melino G., Tobler A., Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death and Differentiation 2001 8 12 1213 1223 10.1038/sj.cdd.4400962 (Pubitemid 34048476)
40. Arvanitis D. A., Lianos E., Soulitzis N., Delakas D., Spandidos D. A., Deregulation of p73 isoform equilibrium in benign prostate hyperplasia and prostate cancer. Oncology Reports 2004 12 5 1131 1137 2-s2.0-16544383365
41. Malaguarnera R., Vella V., Vigneri R., Frasca F., p53 family proteins in thyroid cancer. Endocrine-Related Cancer 2007 14 1 43 60 2-s2.0-34249779859 10.1677/erc.1.01223 (Pubitemid 47521721)
42. Iacono M. L., marco.loiacono@unito.it Monica V., Saviozzi S., Ceppi P., Bracco E., Papotti M., Scagliotti G. V., p63 and p73 isoform expression in non-small cell lung cancer and corresponding morphological normal lung tissue. Journal of Thoracic Oncology 2011 6 3 473 481 10.1097/JTO.0b013e31820b86b0
43. Slatter T. L., Hung N., Campbell H., Rubio C., Mehta R., Renshaw P., Williams G., Wilson M., Engelmann A., Jeffs A., Royds J. A., Baird M. A., Braithwaite A. W., abraithwaite@cmri.usyd.edu.au Hyperproliferation, cancer, and inflammation in mice expressing a Δ133p53-like isoform. Blood 2011 117 19 5166 5177 10.1182/blood-2010-11-321851
44. Maier B., Gluba W., Bernier B., Turner T., Mohammad K., Guise T., Sutherland A., Thorner M., Scrable H., Modulation of mammalian life span by the short isoform of p53. Genes and Development 2004 18 3 306 319 2-s2.0-1042266548 10.1101/gad.1162404 (Pubitemid 38199255)
45. Pehar M., O'Riordan K. J., Burns-Cusato M., Andrzejewski M. E., del Alcazar C. G., Burger C., Scrable H., Puglielli L., Altered longevity-assurance activity of p53: p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell 2010 9 2 174 190 2-s2.0-77953261825 10.1111/j.1474-9726.2010.00547.x
46. Ungewitter E., Scrable H., Δ40p53 controls the switch from pluripotency to differentiation by regulating IGF signaling in ESCs. Genes and Development 2010 24 21 2408 2419 2-s2.0-78049423721 10.1101/gad.1987810
47. Song W., Huo S. W., Lü J. J., Liu Z., Fang X. L., Jin X. B., Yuan M. Z., Expression of p53 isoforms in renal cell carcinoma. Chinese Medical Journal 2009 122 8 921 926 2-s2.0-68249138155 10.3760/cma.j.issn.0366-6999.2009.08.008
48. Fujita K., Mondal A. M., Horikawa I., Nguyen G. H., Kumamoto K., Sohn J. J., Bowman E. D., Mathe E. A., Schetter A. J., Pine S. R., Ji H., Vojtesek B., Bourdon J. C., Lane D. P., Harris C. C., p53 isoforms Δ133p53 and p53 β are endogenous regulators of replicative cellular senescence. Nature Cell Biology 2009 11 9 1135 1142 2-s2.0-69949171557 10.1038/ncb1928
49. Boldrup L., Bourdon J. C., Coates P. J., Sjöström B., Nylander K., Expression of p53 isoforms in squamous cell carcinoma of the head and neck. European Journal of Cancer 2007 43 3 617 623 2-s2.0-33846568870 10.1016/j.ejca.2006.10.019 (Pubitemid 46177591)
50. Bourdon J.-C., Khoury M. P., Diot A., Baker L., Fernandes K., Aoubala M., Quinlan P., Purdie C. A., Jordan L. B., Prats A.-C., Lane D. P., Thompson A. M., p53 mutant breast cancer patients expressing p53gamma have as good a prognosis as wild-type p53 breast cancer patients. Breast Cancer Research 2011 13 1, article R7 10.1186/bcr2811
51. Dugani C. B., Paquin A., Fujitani M., Kaplan D. R., Miller F. D., p63 antagonizes p53 to promote the survival of embryonic neural precursor cells. Journal of Neuroscience 2009 29 20 6710 6721 2-s2.0-66249121719 10.1523/JNEUROSCI.5878-08.2009
52. Schwartz D. I., Lindor N. M., Walsh-Vockley C., Roche P. C., Ming M., Smith D. I., Wanguo L., Couch F. J., p73 mutations are not detected in sporadic and hereditary breast cancer. Breast Cancer Research and Treatment 1999 58 1 25 29 2-s2.0-0033453276 10.1023/A:1006237031070 (Pubitemid 30003868)
53. Kovalev S., Marchenko N., Swendeman S., LaQuaglia M., Moll U. M., Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines. Cell Growth and Differentiation 1998 9 11 897 903 2-s2.0-0031766420 (Pubitemid 28514285)
54. Mai M., Huang H., Reed C., Qian C., Smith J. S., Alderete B., Jenkins R., Smith D. I., Liu W., Genomic organization and mutation analysis of p73 in oligodendrogliomas with chromosome 1 p-arm deletions. Genomics 1998 51 3 359 363 2-s2.0-0032143910 10.1006/geno.1998.5387 (Pubitemid 28413202)
55. Yokomizo A., Mai M., Tindall D. J., Cheng L., Bostwick D. G., Naito S., Smith D. I., Liu W., Overexpression of the wild type p73 gene in human bladder cancer. Oncogene 1999 18 8 1629 1633 2-s2.0-0033602251 (Pubitemid 29108063)
56. Nimura Y., Mihara M., Ichimiya S., Sakiyama S., Seki N., Ohira M., Nomura N., Fujimori M., Adachi W., Amano J., He M., Ping Y. M., Nakagawara A., p73, a gene related to p53, is not mutated in esophageal carcinomas. International Journal of Cancer 1998 78 4 437 440 2-s2.0-0031725211 10.1002/(SICI)1097- 0215(19981109)78:4437::AID-IJC8>3.0.CO;2-V (Pubitemid 28481161)
57. Yang A., Walker N., Bronson R., Kaghad M., Oosterwegel M., Bonnin J., Vagner C., Bonnet H., Dikkes P., Sharpe A., McKeon F., Caput D., p73-Deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 2000 404 6773 99 103 2-s2.0-17544363909 10.1038/35003607 (Pubitemid 30143141)
58. Tomasini R., Tsuchihara K., Wilhelm M., Fujitani M., Rufini A., Cheung C. C., Khan F., Itie-Youten A., Wakeham A., Tsao M. S., Iovanna J. L., Squire J., Jurisica I., Kaplan D., Melino G., Jurisicova A., Mak T. W., TAp73 knockout shows genomic instability with infertility and tumor suppressor functions. Genes and Development 2008 22 19 2677 2691 2-s2.0-53549134949 10.1101/gad.1695308
59. Wilhelm M. T., Rufini A., Wetzel M. K., Tsuchihara K., Inoue S., Tomasini R., Itie-Youten A., Wakeham A., Arsenian-Henriksson M., Melino G., Kaplan D. R., Miller F. D., Mak T. W., Isoform-specific p73 knockout mice reveal a novel role for ΔNp73 in the DNA damage response pathway. Genes and Development 2010 24 6 549 560 2-s2.0-77949362925 10.1101/gad.1873910
60. Tannapfel A., John K., Miše N., Schmidt A., Buhlmann S., Ibrahim S. M., Pützer B. M., Autonomous growth and hepatocarcinogenesis in transgenic mice expressing the p53 family inhibitor DNp73. Carcinogenesis 2008 29 1 211 218 2-s2.0-38849116924 10.1093/carcin/bgm236 (Pubitemid 351201761)
61. Stiewe T., Tuve S., Peter M., Tannapfel A., Elmaagacli A. H., Pützer B. M., Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clinical Cancer Research 2004 10 2 626 633 2-s2.0-0842311606 10.1158/1078-0432.CCR-0153-03 (Pubitemid 38174002)
62. Domínguez G., García J. M., Peña C., Silva J., García V., Martínez L., Maximiano C., Gómez M. E., Rivera J. A., García-Andrade C., Bonilla F., felixbv@stnet.es ΔTAp73 upregulation correlates with poor prognosis in human tumors: putative in vivo network involving p73 isoforms, p53, and E2F-1. Journal of Clinical Oncology 2006 24 5 805 815 10.1200/JCO.2005.02.2350 (Pubitemid 46622048)
63. Fillippovich I., Sorokina N., Gatei M., Haupt Y., Hobson K., Moallem E., Spring K., Mould M., Mcguckin M. A., Lavin M. F., Khanna K. K., Transactivation-deficient p73 α (p73Δexon2) inhibits apoptosis and competes with p53. Oncogene 2001 20 4 514 522 2-s2.0-17744386129 10.1038/sj.onc.1204118 (Pubitemid 32158231)
64. Concin N., Becker K., Slade N., Erster S., Mueller-Holzner E., Ulmer H., Daxenbichler G., Zeimet A., Zeillinger R., Marth C., Moll U. M., Transdominant ΔTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Research 2004 64 7 2449 2460 2-s2.0-11144357549 10.1158/0008-5472.CAN-03-1060 (Pubitemid 38523899)
65. Castillo J., Goñi S., Latasa M. U., Perugorría M. J., Calvo A., Muntané J., Bioulac-Sage P., Balabaud C., Prieto J., Avila M. A., Berasain C., cberasain@unav.es Amphiregulin induces the alternative splicing of p73 into its oncogenic isoform ΔEx2p73 in human hepatocellular tumors. Gastroenterology 2009 137 5 1805 1815, article e4 10.1053/j.gastro.2009.07.065
66. Ng S. W., Yiu G. K., Liu Y., Huang L. W., Palnati M., Jun S. H., Berkowitz R. S., Mok S. C., Analysis of p73 in human borderline and invasive ovarian tumor. Oncogene 2000 19 15 1885 1890 2-s2.0-0034611615 (Pubitemid 30219031)
67. O'Nions J., Brooks L. A., Sullivan A., Bell A., Dunne B., Rozycka M., Reddy A., Tidy J. A., Evans D., Farrell P. J., Evans A., Gasco M., Gusterson B., Crook T., p73 is over-expressed in vulval cancer principally as the δ 2 isoform. British Journal of Cancer 2001 85 10 1551 1556 2-s2.0-0035900819 10.1054/bjoc.2001.2138 (Pubitemid 34001589)
68. Tuve S., Wagner S. N., Schitrek B., Pützer B. M., brigitte.puetzer@med.uni-rostock.de Alterations of ΔTA-p73 splice transcripts during melanoma development and progression. International Journal of Cancer 2004 108 1 162 166 10.1002/ijc.11552 (Pubitemid 37444460)
69. Shishikura T., Ichimiya S., Ozaki T., Nimura Y., Kageyama H., Nakamura Y., Sakiyama S., Miyauchi M., Yamamoto N., Suzuki M., Nakajima N., Nakagawara A., Mutational analysis of the p73 gene in human breast cancers. International Journal of Cancer 1999 84 3 321 325 2-s2.0-0033064553 10.1002/(SICI)1097- 0215(19990621)84:3321::AID-IJC21>3.0.CO;2-S (Pubitemid 29256762)
70. Koker M. M., Kleer C. G., p63 expression in breast cancer: a highly sensitive and specific marker of metaplastic carcinoma. American Journal of Surgical Pathology 2004 28 11 1506 1512 2-s2.0-7044246236 10.1097/01.pas. 0000138183.97366.fd (Pubitemid 39425518)
71. Ribeiro-Silva A., Ramalho L. N. Z., Garcia S. B., Zucoloto S., Does the correlation between EBNA-1 and p63 expression in breast carcinomas provide a clue to tumorigenesis in Epstein-Barr virus-related breast malignancies? Brazilian Journal of Medical and Biological Research 2004 37 1 89 95 2-s2.0-1242284672 (Pubitemid 38240149)
72. Hanker L., Karn T., Ruckhaeberle E., Gaetje R., Solbach C., Schmidt M., Engels K., Holtrich U., Kaufmann M., Rody A., Clinical relevance of the putative stem cell marker p63 in breast cancer. Breast Cancer Research and Treatment 2010 122 3 765 775 2-s2.0-77955551438 10.1007/s10549-009-0608-6
73. Tokuchi Y., Hashimoto T., Kobayashi Y., Hayashi M., Nishida K., Hayashi S., Imai K., Nakachi K., Ishikawa Y., Nakagawa K., Kawakami Y., Tsuchiya E., The expression of p73 is increased in lung cancer, independent of p53 gene alteration. British Journal of Cancer 1999 80 10 1623 1629 2-s2.0-0032988708 10.1038/sj.bjc.6690572 (Pubitemid 29308646)
74. Uramoto H., Sugio K., Oyama T., Nakata S., Ono K., Morita M., Funa K., Yasumoto K., Expression of ΔNp73 predicts poor prognosis in lung cancer. Clinical Cancer Research 2004 10 20 6905 6911 2-s2.0-6044259205 10.1158/1078-0432.CCR-04-0290 (Pubitemid 39383040)
75. Di Vinci A., Sessa F., Casciano I., Banelli B., Franzi F., Brigati C., Allemanni G., Russo P., Dominioni L., Romani M., massimo.romani@istge.it Different intracellular compartmentalization of TA and ΔNp73 in non-small cell lung cancer. International Journal of Oncology 2009 34 2 449 456 10.3892/ijo00000169
76. Daskalos A., Logotheti S., Markopoulou S., Xinarianos G., Gosney J. R., Kastania A. N., Zoumpourlis V., Field J. K., Liloglou T., Global DNA hypomethylation-induced ΔNp73 transcriptional activation in non-small cell lung cancer. Cancer Letters 2011 300 1 79 86 2-s2.0-78549270385 10.1016/j.canlet.2010.09.009
77. Pelosi G., Pasini F., Stenholm C. O., Pastorino U., Maisonneuve P., Sonzogni A., Maffini F., Pruneri G., Fraggetta F., Cavallon A., Roz E., Iannucci A., Bresaola E., Viale G., p63 immunoreactivity in lung cancer: yet another player in the development of squamous cell carcinomas? Journal of Pathology 2002 198 1 100 109 2-s2.0-0036724213 10.1002/path.1166 (Pubitemid 34966213)
78. Massion P. P., Taflan P. M., Rahman S. M. J., Yildiz P., Shyr Y., Edgerton M. E., Westfall M. D., Roberts J. R., Pietenpol J. A., Carbone D. P., Gonzalez A. L., Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Research 2003 63 21 7113 7121 2-s2.0-10744221856 (Pubitemid 37413448)
79. Chen F., Chen H., Tao H., Zhang Y., Ye B., Liu M., Different expressions of p53 gene family members and their clinical significance in human non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2004 7 4 339 343 2-s2.0-4344674593 (Pubitemid 39120658)
80. Iwata T., Uramoto H., Sugio K., Fujino Y., Oyama T., Nakata S., Ono K., Morita M., Yasumoto K., A lack of prognostic significance regarding ΔNp63 immunoreactivity in lung cancer. Lung Cancer 2005 50 1 67 73 2-s2.0-24744452608 10.1016/j.lungcan.2005.03.039 (Pubitemid 41297471)
81. Narahashi T., Niki T., Wang T., Goto A., Matsubara D., Funata N., Fukayama M., Cytoplasmic localization of p63 is associated with poor patient survival in lung adenocarcinoma. Histopathology 2006 49 4 349 357 2-s2.0-33748752117 10.1111/j.1365-2559.2006.02507.x (Pubitemid 44401541)
82. Yokomizo A., Mai M., Bostwick D. G., Tindall D. J., Qian J., Cheng L., Jenkins R. B., Smith D. I., Liu W., Mutation and expression analysis of the p73 gene in prostate cancer. Prostate 1999 39 2 94 100 2-s2.0-0033119215 10.1002/(SICI)1097-0045(19990501)39:294::AID-PROS3>3.0.CO;2-W (Pubitemid 29194280)
83. Guan M., mingguan88@yahoo.com Chen Y., Aberrant expression of ΔNp73 in benign and malignant tumours of the prostate: correlation with Gleason score. Journal of Clinical Pathology 2005 58 11 1175 1179 10.1136/jcp.2005. 026955 (Pubitemid 41566462)
84. Parsons J. K., Saria E. A., Nakayama M., Vessella R. L., Sawyers C. L., Isaacs W. B., Faith D. A., Bova G. S., Samathanam C. A., Mitchell R., de Marzo A. M., Comprehensive mutational analysis and mRNA isoform quantification of TP63 in normal and neoplastic human prostate cells. Prostate 2009 69 5 559 569 2-s2.0-61949432240 10.1002/pros.20904
85. Dhillon P. K., Barry M., Stampfer M. J., Perner S., Fiorentino M., Fornari A., Jing M., Fleet J., Kurth T., Rubin M. A., Mucci L. A., Aberrant cytoplasmic expression of p63 and prostate cancer mortality. Cancer Epidemiology Biomarkers and Prevention 2009 18 2 595 600 2-s2.0-60549093217 10.1158/1055-9965.EPI-08-0785
86. Guan M., Peng H. X., Yu B., Lu Y., p73 overexpression and angiogenesis in human colorectal carcinoma. Japanese Journal of Clinical Oncology 2003 33 5 215 220 2-s2.0-0043201364 10.1093/jjco/hyg045 (Pubitemid 43115261)
87. Carneiro F. P., Ramalho L. N. Z., Britto-Garcia S., Ribeiro-Silva A., Zucoloto S., Immunohistochemical expression of p16, p53, and p63 in colorectal adenomas and adenocarcinomas. Diseases of the Colon and Rectum 2006 49 5 588 594 2-s2.0-33646574948 10.1007/s10350-006-0515-4 (Pubitemid 43723805)
88. Chi S. G., Chang S. G., Lee S. J., Lee C. H., Kim J. I., Park J. H., Elevated and biallelic expression of p73 is associated with progression of human bladder cancer. Cancer Research 1999 59 12 2791 2793 2-s2.0-0033564164 (Pubitemid 29283109)
89. Puig P., Capodieci P., Drobnjak M., Verbel D., Prives C., Cordon-Cardo C., Di Como C. J., p73 Expression in human normal and tumor tissues: loss of p73 α expression is associated with tumor progression in bladder cancer. Clinical Cancer Research 2003 9 15 5642 5651 2-s2.0-0344326931 (Pubitemid 37499486)
90. Park B. J., Lee S. J., Kim J. I., Lee S. J., Lee C. H., Chang S. G., Park J. H., Chi S. G., Frequent alteration of p63 expression in human primary bladder carcinomas. Cancer Research 2000 60 13 3370 3374 2-s2.0-0034234312 (Pubitemid 30482148)
91. Koga F., Kawakami S., Fujii Y., Saito K., Ohtsuka Y., Iwai A., Ando N., Takizawa T., Kageyama Y., Kihara K., Impaired p63 expression associates with poor prognosis and uroplakin III expression in invasive urothelial carcinoma of the bladder. Clinical Cancer Research 2003 9 15 5501 5507 2-s2.0-0345189361 (Pubitemid 37499468)
92. Karni-Schmidt O., Castillo-Martin M., HuaiShen T., Gladoun N., Domingo-Domenech J., Sanchez-Carbayo M., Li Y., Lowe S., Prives C., Cordon-Cardo C., cc2791@columbia.edu Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. American Journal of Pathology 2011 178 3 1350 1360 10.1016/j.ajpath.2010.11.061
93. Kroiss M. M., Bosserhoff A. K., Vogt T., Buettner R., Bogenrieder T., Landthaler M., Stolz W., Loss of expression or mutations in the p73 tumour suppressor gene are not involved in the pathogenesis of malignant melanomas. Melanoma Research 1998 8 6 504 509 2-s2.0-0032432810 (Pubitemid 29046501)
94. Kang M. J., Park B. J., Byun D. S., Park J. I., Kim H. J., Park J. H., Chi S. G., Loss of imprinting and elevated expression of wild-type p73 in human gastric adenocarcinoma. Clinical Cancer Research 2000 6 5 1767 1771 2-s2.0-0034112090
95. Tannapfel A., tana@medizin.uni-leipzig.de Schmelzer S., Benicke M., Klimpfinger M., Kohlhaw K., Mössner J., Engeland K., Wittekind C., Expression of the p53 homologues p63 and p73 in multiple simultaneous gastric cancer. Journal of Pathology 2001 195 2 163 170 10.1002/path.947 (Pubitemid 32899024)
96. Vilgelm A. E., Hong S. M., Washington M. K., Wei J., Chen H., El-Rifai W., Zaika A., Characterization of Δnp73 expression and regulation in gastric and esophageal tumors. Oncogene 2010 29 43 5861 5868 2-s2.0-78049338121 10.1038/onc.2010.319
97. Cai Y. C., Yang G. Y., Nie V., Wang L. D., Zhao X., Song Y. L., Seril D. N., Liao J., Xing E. P., Yang C. S., Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53. Carcinogenesis 2000 21 4 683 689 2-s2.0-0034092061 (Pubitemid 30214025)
98. Masuda N., Kato H., Nakajima T., Sano T., Kashiwabara K., Oyama T., Kuwano H., Synergistic decline in expressions of p73 and p21 with invasion in esophageal cancers. Cancer Science 2003 94 7 612 617 2-s2.0-0043063959 10.1111/j.1349-7006.2003.tb01491.x (Pubitemid 36975016)
99. Glickman J. N., Yang A., Shahsafaei A., McKeon F., Odze R. D., Expression of p53-related protein p63 in the gastrointestinal tract and in esophageal metaplastic and neoplastic disorders. Human Pathology 2001 32 11 1157 1165 2-s2.0-0035185632 10.1053/hupa.2001.28951 (Pubitemid 33104425)
100. Geddert H., Kiel S., Heep H. J., Gabbert H. E., Sarbia M., The role of p63 and ΔNp63 (p40) protein expression and gene amplification in esophageal carcinogenesis. Human Pathology 2003 34 9 850 856 10.1016/S0046-8177(03)00342-3 (Pubitemid 37169613)
101. Morita M., Uramoto H., Nakata S., Ono K., Sugaya M., Yoshimatsu T., Oyama T., Hanagiri T., Sugio K., Yasumoto K., Expression of DeltaNp63 in squamous cell carcinoma of the esophagus. Anticancer Research 2005 25 5 3533 3539 2-s2.0-23344431897 (Pubitemid 41105237)
102. Takahashi Y., Noguchi T., Takeno S., Kimura Y., Okubo M., Kawahara K., Reduced expression of p63 has prognostic implications for patients with esophageal squamous cell carcinoma. Oncology Reports 2006 15 2 323 328 2-s2.0-33744486389
103. Cao L. Y., Yin Y., Li H., Jiang Y., Zhang H. F., Expression and clinical significance of S100A2 and p63 in esophageal carcinoma. World Journal of Gastroenterology 2009 15 33 4183 4188 2-s2.0-70449706066 10.3748/wjg.15.4183
104. El-Naggar A. K., Lai S., Clayman G. L., Mims B., Lippman S. M., Coombes M., Luna M. A., Lozano G., P73 gene alterations and expression in primary oral and laryngeal squamous carcinomas. Carcinogenesis 2001 22 5 729 735 2-s2.0-0035030186 (Pubitemid 32447920)
105. Faridoni-Laurens L., Bosq J., Janot F., Vayssade M., Le Bihan M. L., Kaghad M., Caput D., Bénard J., Ahomadegbe J. C., P73 expression in basal layers of head and neck squamous epithelium: a role in differentiation and carcinogenesis in concert with p53 and p63? Oncogene 2001 20 38 5302 5312 2-s2.0-0035974819 10.1038/sj.onc.1204687 (Pubitemid 32844062)
106. Weber A., Bellmann U., Bootz F., Wittekind C., Tannapfel A., Expression of p53 and its homologues in primary and recurrent squamous cell carcinomas of the head and neck. International Journal of Cancer 2002 99 1 22 28 2-s2.0-0036568390 10.1002/ijc.10296 (Pubitemid 34273193)
107. Chen Y. K., Hsue S. S., Lin L. M., p73 expression for human buccal epithelial dysplasia and squamous cell carcinoma: does it correlate with nodal status of carcinoma and is there a relationship with malignant change of epithelial dysplasia? Head and Neck 2004 26 11 945 952 2-s2.0-8444244574 10.1002/hed.20098 (Pubitemid 39488121)
108. Lo Muzio L., Santarelli A., Caltabiano R., Rubini C., Pieramici T., Trevisiol L., Carinci F., Leonardi R., de Lillo A., Lanzafame S., Bufo P., Piattelli A., p63 overexpression associates with poor prognosis in head and neck squamous cell carcinoma. Human Pathology 2005 36 2 187 194 2-s2.0-20044379201 10.1016/j.humpath.2004.12.003 (Pubitemid 40313576)
109. Liu S. S., Chan K. Y. K., Cheung A. N. Y., Liao X. Y., Leung T. W., Ngan H. Y. S., Expression of ΔNp73 and TAp73 α independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clinical Cancer Research 2006 12 13 3922 3927 2-s2.0-33746104471 10.1158/1078-0432.CCR-05-2573 (Pubitemid 44078076)
110. Cheung A. N., anycheun@hkucc.hku.hk Tsun K.-L., Ng K.-M., Szeto E., Siu M. K., Wong E. S., Ngan H. Y., P634A4 and TAp73 immunocytochemistry in liquid-based cervical cytologypotential biomarkers for diagnosis and progress prediction of cervical neoplasia. Modern Pathology 2010 23 4 559 566 10.1038/modpathol.2009.198
111. Wang T. Y., Chen B. F., Yang Y. C., Chen H., Wang Y., Cviko A., Quade B. J., Sun D., Yang A., McKeon F. D., Crum C. P., Histologic and immunophenotypic classification of cervical carcinomas by expression of the p53 homologue p63: a study of 250 cases. Human Pathology 2001 32 5 479 486 2-s2.0-0034986554 10.1053/hupa.2001.24324 (Pubitemid 32506517)
112. Lin Z., Liu M., Li Z., Kim C., Lee E., Kim I., iskim@korea.ac.kr ΔNp63 protein expression in uterine cervical and endometrial cancers. Journal of Cancer Research and Clinical Oncology 2006 132 12 811 816 10.1007/s00432-006-0130-8 (Pubitemid 44521457)
113. Mai M., Qian C., Yokomizo A., Tindall D. J., Bostwick D., Polychronakos C., Smith D. I., Liu W., Loss of imprinting and allele switching of p73 in renal cell carcinoma. Oncogene 1998 17 13 1739 1741 2-s2.0-0032191602 (Pubitemid 28482651)
114. Tuna B., burcin.tuna@deu.edu.tr Unlu M., Asian G., Secil M., Yorukoglu K., Diagnostic and prognostic impact of p63 immunoreactivity in renal malignancies. Analytical and Quantitative Cytology and Histology 2009 31 2 118 122
115. Ferru A., Denis S., Guilhot J., Gibelin H., Tourani J. M., Kraimps J. L., Larsen C. J., Karayan-Tapon L., l.karayan-tapon@chu-poitiers.fr Expression of TAp73 and ΔNp73 isoform transcripts in thyroid tumours. European Journal of Surgical Oncology 2006 32 2 228 230 10.1016/j.ejso.2005.09.014 (Pubitemid 43257129)
116. Ito Y., Uramoto H., Funa K., Yoshida H., Jikuzono T., Asahi S., Higashiyama T., Tomoda C., Takamura Y., Miya A., Kobayashi K., Matsuzuka F., Kuma K., Miyauchi A., Delta Np73 expression in thyroid neoplasms originating from follicular cells. Pathology 2006 38 3 205 209 2-s2.0-33745099534 10.1080/00313020600696298 (Pubitemid 43879714)
117. Malaguarnera R., Mandarino A., Mazzon E., Vella V., Gangemi P., Vancheri C., Vigneri P., Aloisi A., Vigneri R., Frasca F., The p53-homologue p63 may promote thyroid cancer progression. Endocrine-Related Cancer 2005 12 4 953 971 2-s2.0-29144478507 10.1677/erc.1.00968 (Pubitemid 41815789)
118. Ito Y., Takeda T., Wakasa K., Tsujimoto M., Sakon M., Matsuura N.,
119. House M. G., Guo M. Z., Iacobuzio-Donahue C., Herman J. G., Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 2003 24 2 193 198 2-s2.0-0037328351 10.1093/carcin/24.2.193 (Pubitemid 36267086)
120. Basturk O., Khanani F., Sarkar F., Levi E., Cheng J. D., Adsay N. V., DeltaNp63 expression in pancreas and pancreatic neoplasia. Modern Pathology 2005 18 9 1193 1198 2-s2.0-30544445278 10.1038/modpathol.3800401 (Pubitemid 43079918)
121. Petrenko O., Zaika A., Moll U. M., ΔNp73 facilitates cell immortalization and cooperates with oncogenic Ras in cellular transformation in vivo. Molecular and Cellular Biology 2003 23 16 5540 5555 2-s2.0-0042977668 10.1128/MCB.23.16.5540-5555.2003 (Pubitemid 36957905)
122. Stiewe T., Zimmermann S., Frilling A., Esche H., Pützer B. M., Transactivation-deficient δ TA-p73 acts as an oncogene. Cancer Research 2002 62 13 3598 3602 2-s2.0-0036628511
123. Cam H., Griesmann H., Beitzinger M., Hofmann L., Beinoraviciute-Kellner R., Sauer M., Hüttinger-Kirchhof N., Oswald C., Friedl P., Gattenlöhner S., Burek C., Rosenwald A., Stiewe T., p53 family members in myogenic differentiation and rhabdomyosarcoma development. Cancer Cell 2006 10 4 281 293 2-s2.0-33749433216 10.1016/j.ccr.2006.08.024 (Pubitemid 44512191)
124. Casciano I., Banelli B., Croce M., Allemanni G., Ferrini S., Tonini G. P., Ponzoni M., Romani M., Role of methylation in the control of ΔNp73 expression in neuroblastoma. Cell Death and Differentiation 2002 9 3 343 345 2-s2.0-0036123047 10.1038/sj.cdd.4400992 (Pubitemid 34223878)
125. Vilgelm A., Wei J. X., Piazuelo M. B., Washington M. K., Prassolov V., El-Rifai W., Zaika A., ΔNp73 α regulates MDR1 expression by inhibiting p53 function. Oncogene 2008 27 15 2170 2176 2-s2.0-41649120554 10.1038/sj.onc.1210862 (Pubitemid 351483384)
126. Uramoto H., Sugio K., Oyama T., Nakata S., Ono K., Nozoe T., Yasumoto K., Expression of the p53 family in lung cancer. Anticancer Research 2006 26 3 1785 1790 2-s2.0-33745595067 (Pubitemid 43989432)
127. Müller M., Schilling T., Sayan A. E., Kairat A., Lorenz K., Schulze-Bergkamen H., Oren M., Koch A., Tannapfel A., Stremmel W., Melino G., Krammer P. H., TAp73/ΔNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death and Differentiation 2005 12 12 1564 1577 2-s2.0-27944476397 10.1038/sj.cdd.4401774 (Pubitemid 41679162)
128. Wager M., Guilhot J., Blanc J. L., Ferrand S., Milin S., Bataille B., Lapierre F., Denis S., Chantereau T., Larsen C. J., Karayan-Tapon L., Prognostic value of increase in transcript levels of Tp73 ΔEx2-3 isoforms in low-grade glioma patients. British Journal of Cancer 2006 95 8 1062 1069 2-s2.0-33750256397 10.1038/sj.bjc.6603410 (Pubitemid 44608169)
129. Meier M., den Boer M. L., Meijerink J. P. P., Broekhuis M. J. C., Passier M. M. C. J., van Wering E. R., Janka-Schaub G. E., Pieters R., Differential expression of p73 isoforms in relation to drug resistance in childhood T-lineage acute lymphoblastic leukaemia. Leukemia 2006 20 8 1377 1384 2-s2.0-33746106468 10.1038/sj.leu.2404288 (Pubitemid 44084050)
130. Concin N., Hofstetter G., Berger A., Gehmacher A., Reimer D., Watrowski R., Tong D., Schuster E., Hefler L., Heim K., Mueller-Holzner E., Marth C., Moll U. M., Zeimet A. G., Zeillinger R., Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo. Clinical Cancer Research 2005 11 23 8372 8383 2-s2.0-28544445114 10.1158/1078-0432.CCR-05-0899 (Pubitemid 41746950)
131. Beitzinger M., Hofmann L., Oswald C., Beinoraviciute-Kellner R., Sauer M., Griesmann H., Bretz A. C., Burek C., Rosenwald A., Stiewe T., p73 poses a barrier to malignant transformation by limiting anchorage-independent growth. EMBO Journal 2008 27 5 792 803 2-s2.0-40949101720 10.1038/emboj.2008.13 (Pubitemid 351506677)
132. Corn P. G., Kuerbitz S. J., van Noesel M. M., Esteller M., Compitello N., Baylin S. B., Herman J. G., Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation. Cancer Research 1999 59 14 3352 3356 2-s2.0-0033565514 (Pubitemid 29334490)
133. Shen L. L., Toyota M., Kondo Y., Obata T., Daniel S., Pierce S., Imai K., Kantarjian H. M., Issa J. P. J., Garcia-Manero G., Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia. Blood 2003 101 10 4131 4136 2-s2.0-0037625237 10.1182/blood-2002-08-2466 (Pubitemid 36857895)
134. Garcia-Manero G., Daniel J., Smith T. L., Kornblau S. M., Lee M. S., Kantarjian H. M., Issa J. P. J., DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clinical Cancer Research 2002 8 7 2217 2224 2-s2.0-0035992430 (Pubitemid 34753593)
135. Vikhanskaya F., Toh W. H., Dulloo I., Wu Q., Boominathan L., Ng H. H., Vousden K. H., Sabapathy K., p73 supports cellular growth through c-Jun-dependent AP-1 transactivation. Nature Cell Biology 2007 9 6 698 706 2-s2.0-34447568465 10.1038/ncb1598 (Pubitemid 47214733)
136. Tschan M. P., Grob T. J., Peters U. R., Laurenzi V. D., Huegli B., Kreuzer K. A., Schmidt C. A., Melino G., Fey M. F., Tobler A., Cajot J. F., Enhanced p73 expression during differentiation and complex p73 isoforms in myeloid leukemia. Biochemical and Biophysical Research Communications 2000 277 1 62 65 2-s2.0-0034649230 10.1006/bbrc.2000.3627
137. Hagiwara K., McMenamin M. G., Miura K., Harris C. C., Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers. Cancer Research 1999 59 17 4165 4169 2-s2.0-0033199888 (Pubitemid 29418718)
138. Sunahara M., Shishikura T., Takahashi M., Todo S., Yamamoto N., Kimura H., Kato S., Ishioka C., Ikawa S., Ikawa Y., Nakagawara A., Mutational analysis of p51A/TAp63 γ a p53 homolog, in non-small cell lung cancer and breast cancer. Oncogene 1999 18 25 3761 3765 2-s2.0-0033600126 10.1038/sj.onc.1202972 (Pubitemid 29338509)
139. Hibi K., Trink B., Patturajan M., Westra W. H., Caballero O. L., Hill D. E., Ratovitski E. A., Jen J., Sidransky D., AIS is an oncogene amplified in squamous cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America 2000 97 10 5462 5467 2-s2.0-0034625043 10.1073/pnas.97.10.5462 (Pubitemid 30313741)
140. Keyes W. M., bill.keyes@crg.es Pecoraro M., Aranda V., Vernersson-Lindahl E., Li W., Vogel H., Guo X., Garcia E. L., Michurina T. V., Enikolopov G., Muthuswamy S. K., Mills A. A., mills@cshl.edu Δnp63 α is an oncogene that targets chromatin remodeler Lsh to drive skin stem cell proliferation and tumorigenesis. Cell Stem Cell 2011 8 2 164 176 10.1016/j.stem.2010.12.009
141. Mills A. A., Zheng B., Wang X. J., Vogel H., Roop D. R., Bradley A., p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature 1999 398 6729 708 713 2-s2.0-0033594491 10.1038/19531 (Pubitemid 29197649)
142. Yang A., Schweitzer R., Sun D., Kaghad M., Walker N., Bronson R. T., Tabin C., Sharpe A., Caput D., Crum C., McKeon F., p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 1999 398 6729 714 718 2-s2.0-0033594485 10.1038/19539 (Pubitemid 29197650)
143. Flores E. R., Sengupta S., Miller J. B., Newman J. J., Bronson R., Crowley D., Yang A., McKeon F., Jacks T., Tumor predisposition in mice mutant for p63 and p73: evidence for broader tumor suppressor functions for the p53 family. Cancer Cell 2005 7 4 363 373 2-s2.0-17444390129 10.1016/j.ccr.2005.02. 019 (Pubitemid 40544653)
144. Koster M. I., Kim S., Mills A. A., DeMayo F. J., Roop D. R., p63 is the molecular switch for initiation of an epithelial stratification program. Genes and Development 2004 18 2 126 131 2-s2.0-0942301281 10.1101/gad.1165104 (Pubitemid 38141780)
145. Romano R. A., Ortt K., Birkaya B., Smalley K., Sinha S., An active role of the ΔN isoform of p63 in regulating basal keratin genes K5 and K14 and directing epidermal cell fate. PLoS ONE 2009 4 5 2-s2.0-66049096917 10.1371/journal.pone.0005623 e5623
146. Crook T., Nicholls J. M., Brooks L., O'Nions J., Allday M. J., High level expression of ΔN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC)? Oncogene 2000 19 30 3439 3444 2-s2.0-0034644195 (Pubitemid 30479339)
147. Yamaguchi K., Wu L., Caballero O. L., Hibi K., Trink B., Resto V., Cairns P., Okami K., Koch W. M., Sidransky D., Jen J., Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. International Journal of Cancer 2000 86 5 684 689 2-s2.0-0034099274 (Pubitemid 30249880)
148. Compérat E., evacomperat@yahoo.fr Bièche I., Dargère D., Ferlicot S., Laurendeau I., Benoît G., Vieillefond A., Verret C., Vidaud M., Capron F., Bedossa P., Paradis V., p63 gene expression study and early bladder carcinogenesis. Urology 2007 70 3 459 462 10.1016/j.urology.2007. 04.030 (Pubitemid 47464492)
149. Marchini S., marchini@marionegri.it Marabese M., Marrazzo E., Mariani P., Cattaneo D., Fossati R., Compagnoni A., Fruscio R., Lissoni A. A., Broggini M., ΔNp63 expression is associated with poor survival in ovarian cancer. Annals of Oncology 2008 19 3 501 507 10.1093/annonc/mdm519 (Pubitemid 351325671)
150. Barbieri C. E., Tang L. J., Brown K. A., Pietenpol J. A., Loss of p63 leads to increased cell migration and up-regulation of genes involved in invasion and metastasis. Cancer Research 2006 66 15 7589 7597 2-s2.0-33747872417 10.1158/0008-5472.CAN-06-2020 (Pubitemid 44289215)
151. Adorno M., Cordenonsi M., Montagner M., Dupont S., Wong C., Hann B., Solari A., Bobisse S., Rondina M. B., Guzzardo V., Parenti A. R., Rosato A., Bicciato S., Balmain A., Piccolo S., A Mutant-p53/Smad complex opposes p63 to empower TGF β -induced metastasis. Cell 2009 137 1 87 98 2-s2.0-63049136592 10.1016/j.cell.2009.01.039
152. Truong A. B., Kretz M., Ridky T. W., Kimmel R., Khavari P. A., p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes and Development 2006 20 22 3185 3197 2-s2.0-33751230475 10.1101/gad.1463206 (Pubitemid 44790632)
153. Leong C. O., Vidnovic N., DeYoung M. P., Sgroi D., Ellisen L. W., The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. Journal of Clinical Investigation 2007 117 5 1370 1380 2-s2.0-34248166978 10.1172/JCI30866 (Pubitemid 46718425)
154. Rocco J. W., Leong C. O., Kuperwasser N., DeYoung M. P., Ellisen L. W., p63 mediates survival in squamous cell carcinoma by suppression of p73-dependent apoptosis. Cancer Cell 2006 9 1 45 56 2-s2.0-30344450404 10.1016/j.ccr.2005.12. 013 (Pubitemid 43069510)
155. Guo X., Keyes W. M., Papazoglu C., Zuber J., Li W., Lowe S. W., Vogel H., Mills A. A., TAp63 induces senescence and suppresses tumorigenesis in vivo. Nature Cell Biology 2009 11 12 1451 1457 2-s2.0-73349088166
156. Djelloul S., Tarunina M., Barnouin K., Mackay A., Jat P. S., Differential protein expression, DNA binding and interaction with SV40 large tumour antigen implicate the p63-family of proteins in replicative senescence. Oncogene 2002 21 7 981 989 2-s2.0-0037034206 10.1038/sj/onc/1205253 (Pubitemid 34174510)
157. Wang D.-Y., Cheng C.-C., Kao M.-H., Hsueh Y.-J., Ma D. H. K., Chen J.-K., jkc508@mail.cgu.edu.tw Regulation of limbal keratinocyte proliferation and differentiation by TAp63 and ΔNp63 transcription factors. Investigative Ophthalmology and Visual Science 2005 46 9 3102 3108 10.1167/iovs.05-0051 (Pubitemid 44264294)
158. Guo W., Fan S., Jiang Y., Chen J., Li Z., Niu H., The expression of p63 gene in human non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2004 7 1 31 34 (Pubitemid 38250139)
159. Su X., Chakravarti D., Cho M. S., Liu L., Gi Y. J., Lin Y. L., Leung M. L., El-Naggar A., Creighton C. J., Suraokar M. B., Wistuba I., Flores E. R., TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature 2010 467 7318 986 990 2-s2.0-77958558613 10.1038/nature09459
160. Wang S., El-Deiry W. S., p73 or p53 directly regulates human p53 transcription to maintain cell cycle checkpoints. Cancer Research 2006 66 14 6982 6989 2-s2.0-33746865877 10.1158/0008-5472.CAN-06-0511 (Pubitemid 44197673)
161. Chen X., Zheng Y., Zhu J., Jiang J., Wang J., p73 is transcriptionally regulated by DNA damage, p53, and p73. Oncogene 2001 20 6 769 774 2-s2.0-0035825577 10.1038/sj.onc.1204149 (Pubitemid 32179345)
162. Wang J., Liu Y. X., Hande M. P., Wong A. C., Jin Y. J., Yin Y., TAp73 is a downstream target of p53 in controlling the cellular defense against stress. Journal of Biological Chemistry 2007 282 40 29152 29162 2-s2.0-35748958407 10.1074/jbc.M703408200 (Pubitemid 350043378)
163. Johnson J., Lagowski J., Lawson S., Liu Y., Kulesz-Martin M., p73 expression modulates p63 and Mdm2 protein presence in complex with p53 family-specific DNA target sequence in squamous cell carcinogenesis. Oncogene 2008 27 19 2780 2787 2-s2.0-42549142975 10.1038/sj.onc.1210941 (Pubitemid 351581473)
164. Strano S., Fontemaggi G., Costanzo A., Rizzo M. G., Monti O., Baccarini A., Sal G. D., Levrero M., Sacchi A., Oren M., Blandino G., Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. Journal of Biological Chemistry 2002 277 21 18817 18826 2-s2.0-18544364361 10.1074/jbc.M201405200 (Pubitemid 34952441)
165. Di Como C. J., Gaiddon C., Prives C., p73 Function is inhibited by tumor-derived p53 mutants in mammalian cells. Molecular and Cellular Biology 1999 19 2 1438 1449 2-s2.0-0032951530 (Pubitemid 29046885)
166. Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C., A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Molecular and Cellular Biology 2001 21 5 1874 1887 2-s2.0-0035131701 10.1128/MCB.21.5.1874-1887.2001 (Pubitemid 32156407)
167. Pozniak C. D., Radinovic S., Yang A., McKeon F., Kaplan D. R., Miller F. D., An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 2000 289 5477 304 306 2-s2.0-0034647718 10.1126/science.289.5477.304 (Pubitemid 30469909)
168. Liu G., Nozell S., Xiao H., Chen X., ΔNp73 β is active in transactivation and growth suppression. Molecular and Cellular Biology 2004 24 2 487 501 2-s2.0-0346725958 10.1128/MCB.24.2.487-501.2004 (Pubitemid 38057903)
169. Flores E. R., Tsai K. Y., Crowley D., Sengupta S., Yang A., McKeon F., Jacks T., p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature 2002 416 6880 560 564 2-s2.0-0037041392 10.1038/416560a (Pubitemid 34288861)
170. Cui R., Nguyen T. T., Taube J. H., Stratton S. A., Feuerman M. H., Barton M. C., Family members p53 and p73 act together in chromatin modification and direct repression of α -fetoprotein transcription. Journal of Biological Chemistry 2005 280 47 39152 39160 2-s2.0-28244491462 10.1074/jbc.M504655200 (Pubitemid 41713866)
171. Yang A., Zhu Z., Kettenbach A., Kapranov P., McKeon F., Gingeras T. R., Struhl K., Genome-wide mapping indicates that p73 and p63 Co-occupy target sites and have similar DNA-binding profiles in vivo. PLoS ONE 2010 5 7 2-s2.0-77955351317 10.1371/journal.pone.0011572 e11572